POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE - Generic Drug Details

What are the generic sources for polymyxin b sulfate; trimethoprim sulfate and what is the scope of patent protection?

Polymyxin b sulfate; trimethoprim sulfate is the generic ingredient in two branded drugs marketed by Allergan, Bausch And Lomb, Epic Pharma Llc, Sandoz, and Somerset Theraps Llc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Ten suppliers are listed for this compound.

Summary for POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	10
DailyMed Link:	POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE at DailyMed

Pharmacology for POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

Drug Class	Dihydrofolate Reductase Inhibitor Antibacterial Polymyxin-class Antibacterial
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

J01EA	Trimethoprim and derivatives
J01E	SULFONAMIDES AND TRIMETHOPRIM
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01XB	Polymyxins
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	POLYTRIM	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	050567-001	Oct 20, 1988		DISCN	Yes	No
Sandoz	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	064211-001	Apr 13, 1998	AT	RX	No	Yes
Somerset Theraps Llc	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	211572-001	Aug 5, 2024	AT	RX	No	No
Bausch And Lomb	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	064120-001	Feb 14, 1997	AT	RX	No	No
Epic Pharma Llc	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	065006-001	Dec 17, 1998	AT	RX	No	No

Market Dynamics and Financial Trajectory for PolyxMyxin B Sulfate and Trimethoprim Sulfate

Last updated: February 14, 2026

Overview
PolyxMyxin B Sulfate and Trimethoprim Sulfate are antibiotics used primarily for bacterial infections. PolyxMyxin B acts against gram-negative bacteria by disrupting cell membrane integrity, while Trimethoprim inhibits bacterial folic acid synthesis. Both drugs are integral to various treatment regimens, with PolyxMyxin B traditionally used in hospital settings for severe infections and Trimethoprim often prescribed for urinary tract infections and prophylaxis.

---

Market Size and Growth Projections

The global antibiotics market reached an estimated USD 55.2 billion in 2022. The segment for polyxMyxin B and Trimethoprim is a subset of this, driven by resistance patterns and medical guidelines.

Key Market Drivers

• Rising antimicrobial resistance (AMR) pressures enhance demand for existing antibiotics like PolyxMyxin B and Trimethoprim.
• Increasing prevalence of healthcare-associated infections, especially in intensive care units.
• Expanding use of combination therapies, with PolyxMyxin B often paired with other antibiotics.
• Growing outpatient treatment of urinary tract infections with Trimethoprim.

Market Challenges

• Adoption barriers based on toxicity profiles and adverse effect concerns, especially with PolyxMyxin B (nephrotoxicity and neurotoxicity) and Trimethoprim (hematological adverse effects).
• Regulatory scrutiny, especially concerning drug toxicity and resistance development.
• Competition from newer antibiotics and alternative therapies.

Forecasts

The antibiotics segment, including PolyxMyxin B and Trimethoprim, is expected to grow at a compound annual growth rate (CAGR) of 2.8% from 2022 to 2030. This reflects steady demand but also indicates saturation in certain markets.

Market Share and Competitive Landscape

Market Players include Pfizer, Hikma Pharmaceuticals, Sandoz, Mylan, and generic manufacturers dominating supply. The market for PolyxMyxin B and Trimethoprim primarily exists within generic product lines, with limited branded options.

Patented formulations are largely phased out, with most sales driven by generics.

Pricing and Revenue Trends

• PolyxMyxin B historically sold at higher prices in hospitals, with prices around USD 15–25 per vial.
• Trimethoprim trade prices vary regionally, around USD 0.05–0.20 per tablet, with higher margins for branded formulations.
• Growing global supply of generics has led to price erosion, especially in mature markets like the US and Europe, where price declines of 5–10% annually are observed.

Regulatory Environment

• Market access hinges on approvals from agencies such as the FDA and EMA.
• Recent updates focus on revised safety profiles, with warning labels for toxicity.
• Use restrictions and stewardship programs influence prescription patterns, impacting revenue streams.

---

Financial Trajectory Analysis

Revenue Contributions

• PolyxMyxin B: Primarily hospital-based sales, contributing approximately USD 1.2 billion globally in 2022.
• Trimethoprim: Broader outpatient use, estimated at USD 750 million, with significant growth in emerging markets.

Historical Growth Trends

• PolyxMyxin B experienced slow growth, with an increase of approximately 1–2% annually, constrained by toxicity concerns.
• Trimethoprim has seen moderate growth, with its popularity driven by outpatient settings and combination therapies such as Bactrim.

Future Revenue Projections

• PolyxMyxin B: Expected to grow at ~2% CAGR, constrained by toxicity management and increasing use of alternative agents.
• Trimethoprim: Forecasted to grow at around 3%, aided by expanding use in developing regions and combination therapies.

Investment Considerations

• Companies investing in improved formulations or safety profiles could see preferential prescribing.
• Patent expirations mainly impact non-branded versions; branded sales are declining.
• Supply chain stability, especially during global disruptions, will influence market supply and pricing.

---

Key Market Dynamics Summary

Aspect	Details
Market size (2022)	USD 2.95 billion (estimate for PolyxMyxin B & Trimethoprim)
Growth rate (2022-2030)	2.8% CAGR overall
Key drivers	AMR, infection prevalence, outpatient use
Challenges	Toxicity, resistance, regulatory oversight
Major players	Pfizer, Hikma, Sandoz, Mylan

---

Key Takeaways

• The market for PolyxMyxin B and Trimethoprim is stable but mature, with slow growth driven by resistance and infection rates.
• Price erosion due to generics affects revenue margins, but demand persists due to medical necessity.
• Safety concerns and regulatory updates influence prescribing and market acceptance.
• Emerging markets offer growth prospects, particularly for Trimethoprim.
• Innovation focusing on safer formulations and combination regimens could alter market dynamics.

---

FAQs

1. What factors influence the pricing of PolyxMyxin B and Trimethoprim?
   Prices are driven by manufacturing costs, patent status, brand versus generic status, region, and regulatory requirements. Generics lead to price competition, lowering margins.

2. How does antimicrobial resistance impact this market?
   Resistance reduces the efficacy of both drugs, necessitating higher doses, combination therapies, or alternative agents, which can limit revenue growth.

3. What regulatory changes could affect market access?
   Enhanced safety monitoring, labeling updates for toxicity, and restrictions on use can affect sales volumes and reformulation efforts.

4. Are there opportunities for new formulations?
   Yes, formulations with improved safety or delivery methods, such as liposomal or targeted delivery systems, could regain market share.

5. What regional differences affect market dynamics?
   Developed countries have mature markets with slow growth, while emerging markets show expanding demand due to higher infection rates and lower drug penetration.

---

References

1. [1] Zion Market Research, "Antibiotics Market by Type," 2022.
2. [2] IMARC Group, "Global Antibiotics Market Size," 2022.
3. [3] U.S. Food and Drug Administration (FDA), drug approval and safety updates.
4. [4] European Medicines Agency (EMA), antimicrobial resistance policy updates.